» Articles » PMID: 39821694

LGR5: An Emerging Therapeutic Target for Cancer Metastasis and Chemotherapy Resistance

Overview
Date 2025 Jan 17
PMID 39821694
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer stem cells play an important role in tumor progression and chemotherapy resistance. Leucine-rich G repeat-containing protein-coupled receptor 5 (LGR5) has been identified as a cancer stem cell marker in several cancer types. LGR5 is involved in cancer development and progression via several pathways including WNT/β-catenin signaling pathway. LGR5 plays a role in tumor progression by promoting cancer cell migration, invasion, metastasis, and angiogenesis in many cancers including colorectal, brain, gastric, and ovarian cancer. This review summarises the current knowledge on the expression and functional role of LGR5 in cancers, the molecular mechanisms regulated by LGR5, and the relationship between LGR5 and chemotherapy resistance. The review also includes highlights potential strategies to inhibit LGR5 expression and function. The majority of functional studies have shown that LGR5 plays an important role in promoting cancer progression, metastasis and chemotherapy resistance however, in some contexts LGR5 can also activate tumor-suppressive pathways and LGR5 negative cells can also promote cancer progression. The review highlights that targeting LGR5 is a promising anti-cancer treatment but the functional effect of LGR5 on tumor cells is complex may be dependent on cancer type, tumor microenvironment and cross-talk with other molecules in the LGR5 signaling pathway.

References
1.
Zhou X, Geng L, Wang D, Yi H, Talmon G, Wang J . R-Spondin1/LGR5 Activates TGFβ Signaling and Suppresses Colon Cancer Metastasis. Cancer Res. 2017; 77(23):6589-6602. PMC: 5898809. DOI: 10.1158/0008-5472.CAN-17-0219. View

2.
Yu L, Mao X, Wu S, Zhou L, Song W, Gong X . The correlation of the expressions of WWOX, LGR5 and vasohibin-1 in epithelial ovarian cancer and their clinical significance. Int J Clin Exp Pathol. 2020; 12(1):327-336. PMC: 6944017. View

3.
Wong C, Mulero M, Barth E, Wang K, Shang X, Tikle S . Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian Cancer. J Pharmacol Exp Ther. 2023; 385(2):95-105. PMC: 10108443. DOI: 10.1124/jpet.122.001495. View

4.
Hou M, Chen P, Chu P . LGR5 overexpression confers poor relapse-free survival in breast cancer patients. BMC Cancer. 2018; 18(1):219. PMC: 5824537. DOI: 10.1186/s12885-018-4018-1. View

5.
Wang B, Chen Q, Cao Y, Ma X, Yin C, Jia Y . LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1. PLoS One. 2016; 11(12):e0168904. PMC: 5199039. DOI: 10.1371/journal.pone.0168904. View